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ABSTRACT 
 
Epidermal fatty acid-binding protein (E-FABP) is a lipid carrier, originally discovered in human epidermis. 
We show that E-FABP is almost exclusively expressed in post mitotic (PM) keratinocytes, corresponding 
to its localization in the highest suprabasal layers, while it is barely expressed in keratinocyte stem (KSC) 
and transit amplifying (TA) keratinocytes. Transfection of normal human keratinocytes with recombinant 
(r) E-FABP induces overexpression of K10 and involucrin. On the other hand, E-FABP inhibition by siRNA 
downregulates K10 and involucrin expression in normal keratinocytes through NF-κB and JNK signaling 
pathway. E-FABP is highly expressed in psoriatic epidermis, and it is mainly localized in stratum 
spinosum. Psoriatic PM keratinocytes overexpress E-FABP as compared to the same population in 
normal epidermis. E-FABP inhibition in psoriatic keratinocytes markedly reduces differentiation, while it 
upregulates psoriatic markers such as survivin and K16. However, under high calcium conditions, E-
FABP-silencing downregulates K10 and involucrin, while survivin and K16 expression is completely 
abolished. These data strongly indicate that E-FABP plays an important role in keratinocyte 
differentiation. Moreover, E-FABP modulates differentiation in psoriatic keratinocytes.  
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INTRODUCTION 
  
Epidermal differentiation is a physiological mechanism characterized by morphological changes and by 
the expression of a variety of markers. Changes in keratinocyte differentiation are associated with 
variation in lipid composition of epidermal layers (1). During this process, keratinocytes start to express 
lipid carriers, including high amounts of Epidermal-Fatty Acid Binding Protein (E-FABP) (2). E-FABP 
belongs to the family of FABP proteins and represents the epidermal subtype. E-FABP is not exclusively 
expressed in epidermis (3,4), but it is also detected in adipose tissue, endothelial cells, brain, liver, kidney 
and mammary tissue (5). E-FABP fulfills different roles, including fatty acid transport, control of fatty acids 
metabolism and cell migration (6). It also regulates cytokine productions (7), and it is related to all-trans 
retinoic acid sensitivity in cancer cells (8, 9). E-FABP is capable of binding other types of long-chain fatty 
acids and transporting them from the inner plasma membrane to different cell compartments (10). When 
fatty acids are transported to the nucleus, binding of FABPs to transcription factors of the PPAR family, 
may activate the differentiation process (10,11,12). E-FABP is involved in the differentiation mechanism of 
several cell types, such as T-helper cells, neural cells and mouse keratinocytes (13, 14, 15).  
Psoriasis is an immuno-mediated, hyperproliferative disease characterized by abnormal differentiation of 
epidermis that also displays an altered calcium metabolism and a defective response to extracellular 
calcium gradients (16). E-FABP is overexpressed in psoriatic keratinocytes as compared to normal cells 
(3). Yet, a functional role of E-FABP in human keratinocyte differentiation both in normal and psoriatic 
epidermis remains to be determined.  
Here, we show that either silencing or overexpressing E-FABP markedly affects keratinocyte 
differentiation. We also demonstrate that E-FABP is more expressed in post mitotic (PM) cells from 
psoriatic epidermis than in the same subpopulation from normal skin. Finally, silencing E-FABP alters 
differentiation in psoriatic keratinocytes. 
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METHODS 
 
Cell culture 
Human keratinocytes were obtained from neonatal foreskin, adult and psoriatic skin, and cultured in 
keratinocyte growth medium (KGM) (Lonza, Basel, Switzerland) as described previously (17). To induce 
differentiation cells were grown to 30-40% confluency and treated with 1.8 mM calcium chloride. 
Keratinocyte subpopulations were obtained as previously shown (18,19). Briefly, total keratinocytes were 
first allowed to adhere to human type IV collagen-coated dishes for 5 minutes, to obtain a population 
enriched in keratinocyte stem cells (KSC). Keratinocytes adhering overnight were considered TA cells, as 
previously reported (19). Non adhering cells represent a population of terminally differentiated, post-
mitotic (PM) keratinocytes.  
 
Transfection of normal and psoriatic keratinocytes 
Human keratinocytes, either normal or psoriatic, were plated in antibiotic free KGM medium. After 24 
hours, cells were transfected with 75 nM FABP5 or scrambled siRNA (Thermo Scientific, Denver, CO), 
on-Target plus smart pool human FABP5 or on-Target plus siControl non-targeting pool, combined with 
Lipofectamin 2000 and Opti-MEM (both from Invitrogen, Paisley, UK), according to the manufacturer’s 
instructions. Cells were transfected twice and used 48h later for Western Blotting. Psoriatic and normal 
human keratinocytes transfected with FABP5 siRNA were either treated or untreated with calcium 1.8mM 
immediately after transfection. Cells were lysed or MTT assay was performed on the cells 48h after 
treatment.   
The protein delivery was performed on Gene Pulser System (Bio-Rad Laboratories Inc., CA). Normal 
human keratinocytes were grown under subconfluent conditions in KGM medium, detached from the dish 
and resuspended in 60 µl serum-free DMEM with (+rE-FABP) or without (-rE-FABP) 5 µg of rE-FABP, or 
with the same amount of a 18.8 kDa control protein (Cayman Chemicals, Ann Arbor, MI). Both 
recombinant proteins were purified and delipidated by the manufacturer (Cayman Chemicals) before use. 
The cell suspensions were transferred into two 0.1 cm sterile cuvettes (Bio-Rad), and left in ice for 10 
minutes. The applied current was 100V, 250 µFD, 7.0 ms for +rE-FABP sample, 100V, 250 µFD, 6.9 ms 
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for control protein and 100V, 250 µFD, 6.4 ms for -rE-FABP sample. The treated cells were left in ice for 
10 minutes and either lysed (0h) or transferred into 3X6 cm well plates. To each plate 5 ml of KGM 
medium was added and cells were lysed 48h after.   
 
MTT assay 
Cells were plated in a 96-well tissue culture plate (5,000 cells per well), and MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) assay was performed at 48 and 120 hours after transfection. 
Proliferative cells were detected by incubating with MTT (Sigma-Aldrich) solution at 37°C for 4 hours. The 
formazan dye produced after DMSO solubilization was evaluated by a multiwell scanning 
spectrophotometer at 540 nm. The results are expressed as viability percentage, as compared to control. 
Results are calculated as the mean ± SD of three different experiments. Student’s t-test was performed 
for comparison of the means. 
 
Western blotting analysis 
Total lysates from lesional and non-lesional psoriatic epidermis, and healthy epidermis were obtained as 
follows. Punch biopsies were washed with PBS and treated with dispase II (Roche, Basel, Switzerland) 
overnight at+4°C. The day after, epidermal sheets were separated from the dermis and homogenized in 
RIPA buffer. The study was conducted in accordance to the Declaration of Helsinki Principles, approved 
by the local Ethics Committees of the participating institutions. A total of 12 untreated psoriatic patients 
and 21 healthy controls were enrolled in the study.  
Cultured keratinocytes were washed with PBS and harvested on ice in RIPA buffer at different time points 
or buffer for phosphorylated proteins (50mM Tris-HCl pH 8, 1% NP40, 0.5% sodium deoxycholate, 
150mM NaCl, 0.1% SDS, 1mM Na3VO4, 5mM NaF). Western blotting was performed as previously 
described (18). Membranes were first incubated in blocking buffer then overnight at 4°C with primary anti-
human FABP5 goat antibody (Ab) (1:1,000; R&D Systems, Inc. Minneapolis, MN), anti-human K10 rabbit 
Ab (1:50,000; Epitomics, Burlingame, CA), anti-human involucrin mouse mAb (1:6,000; Sigma-Aldrich), 
anti-human survivin rabbit Ab (1:1,000; Novus Biologicals, Littleton, CO), anti-human K16 mouse Ab 
(1:200; AbD Serotec, Kidlington, UK), anti-human S100A7 mouse Ab (1:400; Abcam, Cambridge, UK), 
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anti-human mouse NF-κB mAb (1:200; S.Cruz, Biotechnologies, Santa Cruz, CA, USA), anti-human 
rabbit P-NF-κB Ab (1:200; S.Cruz, Biotechnologies), anti-human rabbit active JNK1 Ab (1:5000; Promega, 
Madison, WI, USA), anti-human rabbit IKB-α Ab (1:500; Millipore, Billerica, MA, USA). After further 
washing in PBS/Tween 20, the membranes were incubated with peroxidase conjugated anti-goat IgG 
(1:5,000, Santa Cruz Biotechnologies), or anti-mouse IgG (1:2,000, Dako, Glostrup, Denmark) or anti-
rabbit IgG (1:3,000, Dako) for 45 minutes at room temperature. Membranes were washed and developed 
using the ECL chemiluminescent detection system (Amersham Biosciences UK Limited, Little Chalfont, 
Buckinghamshire, England). This experiment was repeated three times and the membranes were 
reprobed with a mouse monoclonal antibody to β-actin (1:3,000, Sigma-Aldrich) to assess total protein 
loading. The band intensity was quantitatively determined using ImageJ software, and protein levels 
intensity was normalized to β-actin expression.  
 
Immunofluorescence 
Keratinocytes were detached, fixed in 4% buffered PFA for 20 minutes and cytospun onto glass slides, as 
previously described (20). For  cytoplasmic and nuclear staining, keratinocyte subpopulations were 
incubated with anti-FABP5 (1:50; ProteinTech Group) or anti-K10 (1:100, Epitomics) or anti-involucrin 
(1:200, Sigma Aldrich) or anti-ki67 Ab (1:200, Epitomics). Cells were then incubated with Alexa Fluor 546 
anti-rabbit or Alexa Fluor anti-mouse 488 (Invitrogen Corporation). After three washes in PBS, slides were 
stained for 5 minutes with 1 µg/ml Dapi (Sigma-Aldrich), washed and covered with coverslips. 
Micrographs were taken on a Confocal Scanning Laser Microscopy (Leica TCS4D) (Leica, Exton, PA). 
Quantification of immunofluorescence staining was performed by analyzing six representative fields for 
each staining sample. Scoring was done by means of cell counting.  
 
Real Time PCR  
Total RNA was extracted from keratinocytes using TRI Reagent method performed as described by the 
manufacturer (Sigma-Aldrich). One microgram of total RNA extracted was reverse transcribed as 
described by the manufacturer (Roche). Nucleotide sequences of the oligomers used (MWG Biotech, 
Ebersberg, Germany) were: E-FABP-DP 5’-3’: ATGGCCACAGTTCAGCAGCTG, RP 5’-3’: 
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CAGGTGACATTGTTCATGAC; involucrin-DP 5’-3’: GGACTGCCTGAGCAAGAATGTG, RP 5’-3’: 
TAAGCTGCTGCTCTGGGTTT; K10-DP 5’-3’: CCTTCGAAATGTGTCCACTGG, RP 5’-3’: 
CAGGGATTGTTTCAAGGCCA; GAPDH-DP 5’-3’:ACATCGCTCAGACACCATG, RP 5’-
3’:TGTAGTTGAGGTCAATGAAGGG. SYBR green Taq-DNA polymerase mixture (Roche, Basel, 
Switzerland) was used for Real Time PCR using an ABI 7500 (Applied Biosystems, Foster City, CA, 
USA). The differences in cycle number past the threshold (ΔCt) is reflective of differences in the initial 
template concentration in the different samples tested. Data are expressed as fold change relative to 
GAPDH. PCR was carried out at least three times for each sample and the experiment was performed in 
triplicate. Data from each sample were compared with stem cells or healthy PM cells, as calibrators, using 
the Sequence Detection Software, version 1.2.3, according to the Relative Quantification Study method 
(Applied Biosystems). 
 
Statistical analysis  
The Student’s t-test was used to compare the average intensities of western blot bands, average 
viabilities and average cell counts. One or two asterisk indicate a significant difference, 0.01<p<0.05 and 
p<0.01 respectively. 
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RESULTS 
 
E-FABP is expressed in normal human post mitotic keratinocytes   
As previously shown, E-FABP is expressed in the higher spinous layers with a weak pattern that 
intensifies moving upward to the outermost layers, cosistent with increased cell differentiation (Fig. S1a). 
To further evaluate E-FABP localization in epidermis, we separated keratinocyte subpopulations as 
previously shown (14) and analyzed E-FABP expression by western blotting (Fig. 1a), and E-FABP, K10, 
involucrin expression by Real Time PCR (Fig. 1c). E-FABP was mostly expressed in PM keratinocytes, 
while it was weakly detectable in TA and absent in KSC, both at the mRNA and protein level. This was 
also confirmed by immunofluorescence performed on keratinocyte subpopulations, analyzed immediately 
after separation. KSC expressed no E-FABP, involucrin or K10, while only few TA cells blandly expressed 
E-FABP. On the other hand, almost all PM cells expressed E-FABP and involucrin, while K10 was barely 
detected (Fig. 1b). Finally, K10 and involucrin were mostly expressed by PM cells, and weakly stained in 
KSC or TA cells (Fig. 1c) 
 
E-FABP modulates differentiation in normal human keratinocytes through NF-kB  and JNK1  
Because E-FABP is expressed in PM cells, we asked whether this protein could be involved in 
keratinocyte differentiation. Increased E-FABP protein levels in keratinocytes cultured in presence of high 
calcium concentration or under confluent conditions have been previously shown (4). However, a direct 
correlation between RNA and protein levels has not been analyzed. We induced differentiation in human 
keratinocytes either by adding calcium to the medium or by growing cells to confluency. Under calcium-
induced keratinocyte differentiation, E-FABP levels increased in a time-dependent manner up to 96h, both 
at the mRNA (Fig. S1f) and protein level (fig. S1b and d), in parallel with K10 and involucrin expression. 
E-FABP was also overexpressed in confluent keratinocytes from 24h up to 72h, as compared to pre-
confluent cells, both at the mRNA (fig. S1g) and protein level (Fig. S1c and e). Similarly, both involucrin 
and K10 expression increased in confluent keratinocytes (Fig. S1c,e and g).  
Although E-FABP is modulated during keratinocyte differentiation, the ability of E-FABP to stimulate 
human keratinocyte differentiation is not completely understood. We transfected normal human 
 9 
keratinocytes with a recombinant E-FABP protein (rE-FABP). rE-FABP was successfully delivered to the 
cells, as confirmed by the 18kDa band, corresponding to the exogenous protein, at 0h. At the same time 
point, a band corresponding to endogenous E-FABP was equally expressed in -rE-FABP, +rE-FABP cells 
and cells transfected with the control protein (Fig. 2a). On the other hand, at 48h, no band corresponding 
to rE-FABP was visible, while a 10 kDa band appeared, possibly indicating a degradation or a 
modification of the recombinant protein. At this time point, cells transfected with rE-FABP overexpressed 
K10 and involucrin, while the same cells transfected with a control protein fail to induce K10 and 
involucrin increase (Fig. 2b).  
Because E-FABP induces a modulation of differentiation-marker expression, we wanted to confirm this 
finding by silencing E-FABP protein. We transfected human keratinocytes with a FABP5-specific siRNA in 
presence or absence of calcium chloride. As shown in figure 2d, E-FABP protein was successfully 
downregulated by siRNA delivery up to 72h after transfection. E-FABP knockdown induced a reduction of 
K10 and involucrin. In presence of calcium, scramble siRNA but not E-FABPsiRNA induced up-regulation 
of K10 and involucrin expression. Moreover, E-FABP down-regulation induced no changes in cell viability 
at 48 and 120h after transfection (Fig. S2a). Similarly, confocal microscopy confirmed the reduction of 
K10 in siRNA treated cells, and revealed that proliferation rate was not affected by E-FABP silencing, as 
shown by the unchanged expression of Ki67 (Fig. 2c). A semi-quantitative analysis of K10 and Ki67 
staining is reported in figure S2b. To further investigate the role of E-FABP in differentiation, we studied 
NF-kB/JNK1 signaling pathways in human keratinocytes transfected with scramble siRNA or E-FABP 
siRNA, in presence or absence of calcium. As shown in Fig. 2d and S2c, E-FABP silencing reduced the 
levels of activated NF-κB expression (represented by the phosphorylated form of the protein, P- NF-κB) 
but not of total NF-κB. The effect on P-NF-κB was even more evident in presence of calcium. On the 
other hand, E-FABP downregulation increased IkBα expression, in particular in presence of calcium. We 
also evaluated active-JNK1 expression in siRNA treated keratinocytes and found that decreased levels of 
In addition, E-FABP siRNA reduced active-JNK1 expression, while calcium failed to induce JNK1 
activation. Altogether these data suggest that lack of E-FABP decreases differentiation markers through 
NF-kB and JNK signaling pathway. 
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E-FABP expression in psoriatic keratinocyte subpopulations  
Psoriasis is characterized by altered keratinocyte differentiation, and E-FABP expression appears to be 
increased in psoriatic epidermis. E-FABP was more expressed in psoriatic skin as compared to healthy 
skin in vivo (Fig. S3a and b). This was also confirmed by western blotting, showing that lesional psoriatic 
epidermis expresses higher levels of E-FABP, as compared to non-lesional psoriatic or healthy epidermis, 
partially mimicking the expression of involucrin (Fig. 3a and b). Consistently, in psoriatic sections, E-FABP 
and involucrin were mostly detected in high spinous layers (Fig. S3b). Moreover, S100A7 and K16 were 
exclusively expressed in psoriatic epidermis, their expression partially overlapping E-FABP localization in 
the high spinous layers (Fig. S3b). In addition, cytoplasmic survivin, a marker of KSC, was expressed in 
the basal layer of normal epidermis, while it was expressed also in suprabasal psoriatic keratinocytes with 
an almost exclusively nuclear pattern (Fig. S3a and b).   
To further evaluate the differential expression of E-FABP in normal and psoriatic epidermis, we separated 
keratinocyte subpopulations and evaluated E-FABP expression by Real Time PCR and western blotting. 
At the mRNA and protein levels, E-FABP was mostly expressed in PM psoriatic keratinocytes, while it 
was almost undetectable in KSC and TA cells (Fig. 3c, f and S3c respectively). This was in line with 
increased mRNA levels of K10 and involucrin in psoriatic PM keratinocytes as compared to KSC and TA 
cells (Fig. 3d and e). In addition, by comparing equal amounts of PM cell lysates from healthy and 
psoriatic skin, we found that psoriatic PM cells expressed significantly higher levels of E-FABP as 
compared to normal PM cells both at the protein (Fig. 3g and S3d) and mRNA level (Fig. 3h). 
 
E-FABP modulates differentiation and psoriatic markers in psoriasis 
Although psoriatic keratinocytes are difficult to culture (21), low calcium and serum-free conditions allow 
to culture psoriatic cells for multiple passages (22,16). Under these conditions, low passage psoriatic 
keratinocytes expressed higher levels of K10, K16 and S100A7 than normal keratinocytes (Fig. 4a). To 
further evaluate E-FABP role in psoriasis, we treated psoriatic keratinocytes with a siRNA specific for E-
FABP, with or without high calcium concentration. In absence of calcium, E-FABP silencing induced a 
slight decrease of K10 and involucrin expression, while psoriatic markers survivin and K16 were up-
regulated. Upon high calcium conditions, in E-FABP siRNA treated psoriatic keratinocytes, K10 and 
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involucrin expression were further down-regulated, survivin was markedly reduced, while K16 expression 
was completely abolished (Fig. 4b and c).  
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DISCUSSION 
In this work, we show that E-FABP is abundantly expressed in PM keratinocytes both in healthy and 
psoriatic epidermis. Moreover, decreased E-FABP expression deranges keratinocyte differentiation in 
normal and psoriatic cells.  E-FABP is localized in suprabasal layers of healthy epidermis, with increased 
expression in the spinous and granular layers. The lipid composition of cell membranes changes during 
keratinocyte differentiation, increasing from suprabasal layers to the more differentiated stratum 
granulosum and corneum. It has been previously suggested that E-FABP is a potential marker of TA 
keratinocytes in human epidermis (5). However, the method by O’Shaughnessy and colleagues does not 
distinguish between TA and PM subpopulations, including both cell subsets in the Non-Adherent pool of 
keratinocytes.  By separating KSC from TA and PM cells based on β1-integrin expression levels, as 
previously reported (18,19), we show that E-FABP protein is highly expressed in PM cells, while it is 
barely detected in TA and KSC. Indeed, E-FABP is expressed in the highest epidermal layers and PM 
keratinocytes are terminally differentiated cells that do not proliferate in vitro (18). This result indicates the 
possibility of a tight correlation between E-FABP function and the state of keratinocyte differentiation. 
Keratinocyte differentiation is induced by high-calcium conditions and in confluent cells. We show that, 
when keratinocytes are induced to differentiate, E-FABP mRNA and protein increase, along with a higher 
expression of involucrin and K10 protein, suggesting that not only E-FABP is mainly localized in 
differentiated cells in vivo, but it also increases when differentiation is promoted in culture.  
It remained to be determined whether E-FABP is able to induce differentiation in human epidermis (23). 
In the neural system, E-FABP stimulates PC12 cells differentiation by inducing neurite extension (14). 
There is also evidence that E-FABP is actively involved in the differentiation program of murine 
keratinocytes (4,24). E-FABP deficient mice display defects in water barrier functions, albeit having 
normal skin morphology and no major defects in other organs (23, 25). This seems to be in contrast with 
a possible role for E-FABP in keratinocyte differentiation. However, keratinocytes obtained from these 
mice show reduced expression of differentiation markers such as K1, involucrin and loricrin, in absence 
of exogenous ligand, and decreased susceptibility to calcium-induced differentiation, as compared to E-
FABP +/+ cells (15). These findings suggest the presence of still unknown compensatory mechanisms in 
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mice lacking E-FABP expression, which lead to normal development of epidermis. In line with E-FABP 
involvement in the differentiation process of keratinocytes, it has been recently shown that, once bound 
to a specific ligand, E-FABP is able to physically interact with the transcription factor PPARβ, thus 
activating the differentiation program in mouse keratinocytes (13). However, to date no data on human 
keratinocytes indicate an active role of E-FABP in keratinocyte differentiation. In this paper, we show that 
administration of rE-FABP to human keratinocytes induces an increased expression of K10 and 
involucrin. The fact that E-FABP is able to act in absence of ligand could be accounted for by some 
residual fatty acids in the media. Treatment of keratinocytes with rE-FABP also results in the appearance 
of a smaller 10kDa E-FABP protein. This may be due to the degradation of the recombinant protein itself 
(26), or the product of a post-translational modification of rE-FABP. The role of E-FABP in keratinocyte 
differentiation was confirmed by silencing with specific E-FABP siRNA. As expected, E-FABP inhibition 
induced a down-regulation of both K10 and involucrin, indicating that E-FABP stimulates human 
keratinocyte differentiation. E-FABP depletion does not influence keratinocyte viability that appears to be 
slightly affected by decreased differentiation, in line with previous findings (15). In agreement with recent 
reports in mice showing that reduced NF-kB activity is responsible for decreased K10 expression in E-
FABP -/- mouse keratinocytes (15), we report that we report that repression of 
differentiation induced by E-FABP silencing is associated with a reduction of 
activated NF-kB expression in normal human keratinocytes. However, calcium 
treatment did not influence NF-kB expression, as previously suggested (27). 
   In mouse epidermis, activation of PPAR-β/γ signaling, which is mediated also by E-FABP binding, 
reproduces a psoriasis-like phenotype (26). Psoriasis is a skin disease with defects in cell differentiation 
and proliferation. Here we show that E-FABP is abundantly expressed in psoriatic epidermis as 
compared to normal skin, as previously reported (4,28). In normal human skin, E-FABP is mainly 
expressed in granular layers, with a decreased staining from upper to lower spinous layers. By contrast, 
in psoriatic skin, E-FABP is highest in spinous layers, thus behaving as other differentiation markers, 
such as involucrin and K10, suggesting a possible involvement of E-FABP in the altered differentiation 
process observed in psoriasis. It has been shown that increasing the proliferation time period of TA 
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keratinocytes generates a psoriatic phenotype, implying that psoriasis possibly originate by alteration of 
TA cells (29). On the other hand, in the present study, psoriatic PM keratinocytes express higher levels of 
E-FABP than normal PM cells. This suggests that E-FABP identifies keratinocytes that have concluded 
the differentiation program and that do not contribute to the proliferative compartment of the skin. Recent 
works show that cultured psoriatic keratinocytes retain some characteristics of the disease under 
optimized culture conditions (30). We show that psoriatic keratinocytes at early passages, under low-
calcium and serum-free conditions, express K16 and S100A7. Downregulation of E-FABP in these cells 
reduces involucrin and K10 expression, thus showing that E-FABP mediates differentiation also in 
psoriatic cells. Not only E-FABP mediates psoriatic keratinocyte differentiation, but E-FABP depletion 
also up-regulates both K16 and survivin, which are overexpressed in psoriatic cells in vivo. Thus, E-
FABP seems to play an important role in the dysregulated epidermal homeostasis observed in psoriasis. 
This effect is completely abrogated when cells are treated with high calcium. Psoriatic keratinocytes in 
culture display an inborn defect in calcium metabolism, thus being not responsive to high extracellular 
calcium (16). E-FABP down-regulation further reduces psoriatic keratinocytes sensitivity to calcium, 
leading to decreased differentiation and to reduced expression of psoriatic markers. All together, these 
data suggest that E-FABP modulation may alter calcium metabolism and uptake in psoriasis.  
We can conclude that E-FABP is able to induce normal human keratinocyte differentiation, and that its 
up-regulation could partially be involved in the altered differentiation mechanism in psoriasis.  
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LEGENDS FOR ILLUSTRATIONS 
 
Figure 1. E-FABP distribution in human keratinocytes 
(a) Keratinocytes subpopulations from adult healthy individuals were isolated as described in Material and 
Methods and cultured in KGM for one week. Protein extracts from KSC, TA and PM cells were 
immunoblotted with anti-E-FABP antibody. Western blotting is representative of three independent 
experiments. β-actin was used as a loading control. (b) Keratinocyte subpopulations were separated, 
immediately fixed and stained. Confocal microscopy analysis of involucrin, K10 and E-FABP in KSC, TA 
and PM keratinocytes. Bars= 50 µm. (c) Normal human keratinocytes were cultured as in a. RNA was 
extracted and E-FABP, K10 and involucrin mRNA were analyzed by Real Time PCR. KSC were used as 
calibrators. Student’s t-test was used for comparison of the means: *p<0.05 and **p<0.01 
 
Figure 2. E-FABP induces differentiation in normal human keratinocytes 
(a) Normal human keratinocytes were transfected with or without rE-FABP, and lysed at 0h. (b) Cells 
were also transfected with or without rE-FABP and with or without control protein, and lysed at 48h after 
transfection. Western blotting for K10, involucrin and E-FABP expression was performed. (c) 
Representative picture of Ki67 and K10 staining in scrambled and E-FABP siRNA treated keratinocytes 
48h after transfection. Bars= 20 µm. (d) Human keratinocytes were transfected with E-FABP or 
scrambled siRNA in presence or absence of calcium chloride. Cell lysates were analyzed 72h after 
calcium addition for E-FABP, K10, involucrin, active-JNK1, P-NF-κB, total NF-κB and IkBα expression. β-
actin was used as a loading control.  
 
Figure 3. E-FABP expression in psoriatic keratinocytes subpopulations 
(a) Total lysates from normal, lesional (L) and non-lesional (NL) psoriatic epidermis were analysed by 
western blotting for involucrin and E-FABP expression. (b) Relative intensity of the results of a. 
Keratinocytes subpopulations from lesional psoriatic epidermis were separated and cultured for one 
week. Cells were lysed for RNA extraction and Real Time PCR was performed on cDNA for E-FABP (c), 
K10 (d) and involucrin (e) expression. GAPDH was used as a loading control. Psoriatic KSC were used 
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as calibrators. (f) Cells were also lysed and analysed by western blotting for E-FABP protein expression. 
Lysates from PM cells obtained from normal and psoriatic epidermis were compared by western blotting 
(g) and Real Time PCR (h), for E-FABP expression.  Healthy PM cells were used as calibrators. 
Student’s t-test was used for comparison of the means: **p<0.01 
 
Figure 4. E-FABP silencing reduces differentiation in psoriatic keratinocytes 
(a) Total keratinocytes from lesional psoriatic and normal human epidermis were cultured under low 
calcium, serum-free conditions for one week. Cells were then harvested and lysed for western blotting. (b) 
Psoriatic keratinocytes were transfected either with E-FABP or scramble siRNA, and cultured with or 
without high calcium. Cell lysates were collected 48h after calcium addition and analyzed by western 
blotting. β-actin was used as a loading control. (c) Relative intensity of the results of b.  
 
Figure S1. 
(a) Immunohystochemical analysis of normal adult human skin for E-FABP expression. On the left: 
negative control. Bars= 70 µm. (b) Normal human keratinocytes were cultured under subconfluent 
conditions with or without high calcium. Protein were extracted and western blotting analysis was 
performed for involucrin, K10 and E-FABP expression. (c) Normal human keratinocytes were cultured 
under preconfluent or confluent conditions and cells were lysed at the indicated time points. Western 
blotting was performed on the cell lysates. β-actin was used as a loading control. (d) Quantitative 
representation of the results of b. (e) Quantitative representation of the results of c. (f) Normal human 
keratinocytes were cultured as in b for 48h. RNA was extracted and E-FABP, K10 and involucrin mRNA 
was analyzed by Real Time PCR. Control was used as calibrator. (g) Normal human keratinocytes were 
cultured under pre-confluent or confluent conditions as in c. RNA was extracted, retro-transcribed and 
amplified by Real Time PCR for the evaluation of E-FABP, K10 and involucrin expression. Subconfluent 
cells were used as calibrator. Student’s t-test was used for comparison of the means: *p<0.05 and 
**p<0.01 
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Figure S2. (a) Viability of normal human keratinocytes transfected with E-FABP or scrambled siRNA has 
been evaluated by MTT assay at the indicated time points. (b) Scrambled and siRNA treated 
keratinocytes were stained for Ki67 and K10 48h after transfection. Percentage of Ki67 and K10 positive 
cells is represented (see Fig. 2c). (c) Relative intensity of the results in Figure 2d. Student’s t-test was 
used for comparison of the means: *p<0.05 and **p<0.01 
 
Figure S3. (a) Staining of survivin, K10, involucrin, E-FABP, S100A7 and K16 in normal human skin. (b) 
Staining of the markers as in a in lesional psoriatic skin. Bars= 70 µm. (c) Relative intensity of the results 
in Figure 3f. (d) Relative intensity of the results in Figure 3g. Student’s t-test was used for comparison of 
the means: *p<0.05 and **p<0.01 
 
 
 SUPPLEMENTARY MATERIALS 
 
Immunohistochemistry 
Healthy and psoriatic skin biopsies were 4% buffered formalin fixed and paraffin embedded. 4µm tissue 
sections were cut and deparaffinized in xylene and rehydrated in graded alcohol. The slides were first 
boiled in citrate buffer, pH6, for 20 minutes in a standard pressure cooker. Expression of survivin, E-
FABP, K10, involucrin, K15, K16, S100A7 was examined immunohistochemically by incubating the 
samples for 1h at room temperature with the following antibodies: FABP5 antibody (1:50, ProteinTech 
Group Inc, Chicago, IL), cytokeratin 10 antibody (1:100, Epitomics), involucrin antibody (1:200, Sigma-
Aldrich), cytokeratin 16 antibody (1:30 AbD Serotech), S100A7 antibody (1:50, Abcam), survivin antibody 
(1:100, Abcam). After three 5-minute washes in PBS, slides were incubated with secondary antibody for 
45 minutes at room temperature followed by incubation with naphtol phosphate substrate for 10 minutes 
as suggested by the datasheet (Lab Vision Corporation, Fremont CA). Negative controls were obtained 
by omitting primary antibody.  
 
 
